Browse UBE2C

Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00179 Ubiquitin-conjugating enzyme
Function

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000209 protein polyubiquitination
GO:0000819 sister chromatid segregation
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007091 metaphase/anaphase transition of mitotic cell cycle
GO:0007096 regulation of exit from mitosis
GO:0007346 regulation of mitotic cell cycle
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010458 exit from mitosis
GO:0010498 proteasomal protein catabolic process
GO:0010965 regulation of mitotic sister chromatid separation
GO:0010993 regulation of ubiquitin homeostasis
GO:0010994 free ubiquitin chain polymerization
GO:0030071 regulation of mitotic metaphase/anaphase transition
GO:0031145 anaphase-promoting complex-dependent catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0031536 positive regulation of exit from mitosis
GO:0032844 regulation of homeostatic process
GO:0033044 regulation of chromosome organization
GO:0033045 regulation of sister chromatid segregation
GO:0033047 regulation of mitotic sister chromatid segregation
GO:0042176 regulation of protein catabolic process
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044784 metaphase/anaphase transition of cell cycle
GO:0045732 positive regulation of protein catabolic process
GO:0045787 positive regulation of cell cycle
GO:0045840 positive regulation of mitotic nuclear division
GO:0045862 positive regulation of proteolysis
GO:0045931 positive regulation of mitotic cell cycle
GO:0051258 protein polymerization
GO:0051304 chromosome separation
GO:0051306 mitotic sister chromatid separation
GO:0051348 negative regulation of transferase activity
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051443 positive regulation of ubiquitin-protein transferase activity
GO:0051444 negative regulation of ubiquitin-protein transferase activity
GO:0051783 regulation of nuclear division
GO:0051785 positive regulation of nuclear division
GO:0051983 regulation of chromosome segregation
GO:0070936 protein K48-linked ubiquitination
GO:0070979 protein K11-linked ubiquitination
GO:0090068 positive regulation of cell cycle process
GO:0098813 nuclear chromosome segregation
GO:1901987 regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902099 regulation of metaphase/anaphase transition of cell cycle
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1904666 regulation of ubiquitin protein ligase activity
GO:1904667 negative regulation of ubiquitin protein ligase activity
GO:1904668 positive regulation of ubiquitin protein ligase activity
GO:2000058 regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000060 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061631 ubiquitin conjugating enzyme activity
GO:0061650 ubiquitin-like protein conjugating enzyme activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0000152 nuclear ubiquitin ligase complex
GO:0005680 anaphase-promoting complex
GO:0031461 cullin-RING ubiquitin ligase complex
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
Reactome R-HSA-179409: APC-Cdc20 mediated degradation of Nek2A
R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-174048: APC/C
R-HSA-174154: APC/C
R-HSA-176409: APC/C
R-HSA-174178: APC/C
R-HSA-179419: APC
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-174084: Autodegradation of Cdh1 by Cdh1
R-HSA-174184: Cdc20
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-176407: Conversion from APC/C
R-HSA-168256: Immune System
R-HSA-141430: Inactivation of APC/C via direct inhibition of the APC/C complex
R-HSA-141405: Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components
R-HSA-68886: M Phase
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-69618: Mitotic Spindle Checkpoint
R-HSA-176412: Phosphorylation of the APC/C
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-8866652: Synthesis of active ubiquitin
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBE2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBE2C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBE2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.940.0481
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9680.734
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9250.674
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5280.362
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8080.611
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1770.931
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3490.428
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.9860.487
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4920.724
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1880.898
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4340.85
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5150.000717
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBE2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBE2C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBE2C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBE2C
Nameubiquitin-conjugating enzyme E2C
Aliases UBCH10; dJ447F3.2; cyclin-selective ubiquitin carrier protein; mitotic-specific ubiquitin-conjugating enzyme ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBE2C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.